Back to results
US 2022/0016131 A1Published application
Methods for improved treatment of cancer
AssigneeWashington University
InventorsRobi Mitra, Arnav Moudgil, Michael Nathaniel Wilkinson
Life of this patent
Estimating the term…
Abstract
Among the various aspects of the present disclosure is the provision of a methods for increasing chemotherapy sensitivity or decreasing chemotherapy resistance using BET inhibitors.
Claims24
A method of sensitizing cancer cells to a chemotherapeutic agent or treating a subject having cancer cells comprising:
- (i) administering a BET inhibiting agent to a subject or cancer cell in an amount effective to convert cancer cells into a more chemotherapeutically-sensitive state and reduce an amount of stem-like or CD24high cells;
- and
- (ii) administering a chemotherapeutic agent to the cancer cells.
A method of detecting stem-like cells and detecting differentiated, cells in cancer cells comprising:
- measuring a level stem-like cells markers (e.g., CD24high and CD24low) using fluorescent activated cell sorting (FACS), wherein if the cells have a high amount of stem-like cells (e.g., CD24high) compared to differentiated cells (e.g., CD24low), the cells are treated with a BET inhibiting agent before, during, or after chemotherapy.
A method of monitoring a subject receiving cancer treatment comprising:
- measuring a level stem cell related markers (e.g., CD24high and CD24low) using fluorescent activated cell sorting (FACS);
- and
- determining if the subject has an increased amount of stem-like cells (e.g., CD24high) compared to differentiated cells (e.g., CD24low);
- or determining if the subject has an increased amount of stem-like cells (e.g., CD24high) compared to an amount of stem-like cells (e.g., CD24high) prior to cancer treatment.
1 more element
A method of monitoring a subject at risk for relapse comprising:
- measuring a level stem cell related markers (e.g., CD24high and CD24low) using fluorescent activated cell sorting (FACS);
- and
- determining if the subject has an increased amount of stem-like cells (e.g., CD24high) compared to differentiated cells (e.g., CD24low);
- or determining if the subject has an increased amount of stem-like cells (e.g., CD24high) to an amount of differentiated cells (e.g., CD24low) compared to a prior measurement of an amount of stem-like and an amount of differentiated cells.
1 more element
Dependencies are inferred from the claim text.